Printer Friendly

ABBOTT LABORATORIES TO MARKET NEW HEPATITIS C TEST

 ABBOTT LABORATORIES TO MARKET NEW HEPATITIS C TEST
 ABBOTT PARK, Ill., May 6 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today that the U.S. Food and Drug Administration ("FDA") has licensed its second test for detection of antibody to the hepatitis C virus ("HCV"). The test, designated as ABBOTT HCV EIA 2.0, replaces Abbott's single antigen test licensed by the FDA in July 1990. The new test is available in several countries in the European Community, Japan, Australia, South and Central America and the Far East.
 "Non-A Non-B hepatitis is considered to be the developed world's most prevalent transfusion related disease," said David A. Thompson, vice president of diagnostics operations. "The improved sensitivity of Abbott's new HCV test will significantly reduce the incidence of post- transfusion hepatitis and further increase the safety of the world's blood supply."
 The ABBOTT HCV EIA 2.0 (Hepatitis C Virus Encoded Antigen) test detects antibodies to three hepatitis C components; HC-34, representing the viral core and HC-31 and C100-3, representing nonstructural HCV proteins. Presence of the HCV antibody in blood donations has been linked to the development of the HCV infection in blood transfusion recipients.
 The ABBOTT HCV EIA 2.0 will be used by blood banks worldwide for screening blood donors and by laboratories for the diagnosis of HCV in patients suffering clinical symptoms.
 Abbott developed the ABBOTT HCV EIA 2.0 test under terms of a license with Chiron Corp., a California firm that successfully cloned the hepatitis C antigen in 1988.
 Abbott Laboratories is a worldwide manufacturer of health care products employing some 46,000 people. In 1991, the company's sales and net earnings were $6.9 billion and $1.1 billion, respectively, with earnings per share of $2.55.
 -0- 5/6/92
 /CONTACT: Susie Patlovich of Abbott Laboratories, 708-938-8848/
 (ABT) CO: Abbott Laboratories ST: Illinois IN: MTC SU:


TQ -- NY044 -- 7037 05/06/92 11:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1992
Words:319
Previous Article:GENERAL DYNAMICS SHARPENS FOCUS ON CORE BUSINESSES
Next Article:GEICO CORPORATION REPORTS 1992 FIRST QUARTER RESULTS
Topics:


Related Articles
FALSE POSITIVITY PHENOMENON POSES NO HEALTH RISK
ABBOTT LABORATORIES MEETS CHALLENGES OF LABORATORY MEDICINE WITH NEW THIRD-GENERATION INSTRUMENT
ABBOTT LABORATORIES TO MARKET SECOND GENERATION HTLV-I TEST
ABBOTT SCIENTISTS IDENTIFY NEW HEPATITIS VIRUSES
ABBOTT REPORTS INCREASE IN SALES AND EARNINGS IN 1995; SALES RISE 9.4 PERCENT TO $10.0 BILLION, EPS UP 13.4 PERCENT
NEW AIDS TEST
Abbott Laboratories to Market New Test for Retroviruses
Visible Genetics Enters into Agreement With Abbott Laboratories.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters